This is a new application from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network. By the end of 2014, the network will have completed 4 clinical trials testing 7 interventions in approximately 1000 women ages 40-62 with vasomotor (VMS) and other menopause symptoms. In the new application, we propose to conduct a large multicenter trial on a relatively understudied area of menopause - vaginal health and sexual function. The number of US women over age 65 is expected to double by 2022 and approximately 40% will experience bothersome vaginal symptoms, 75% may have vaginal dryness and up to 40% may experience pain with intercourse. To address this vast, understudied problem, we propose in Specific Aim #1 to conduct a 3-arm, randomized, controlled, double-blind, clinical trial among postmenopausal women ages 45-70. We will evaluate the effectiveness of ultra-low dose vaginal estradiol (Vagifem 10 mcg), non-hormonal hydrophilic non-prescriptive vaginal gel (Replens) and placebo in reducing a composite score of vaginal symptoms (dryness, itching, irritation or soreness). Secondary aims include evaluation of sexual function, quality of life, and genitourinary atrophy and the creation of a biorepository of vaginal and blood specimens. In a subset of women, we will also examine whether treatment response is related to: a) the postmenopausal vaginal microbiome; b) vaginal mucosal inflammation; and c) reproductive hormone profiles. The in-depth focus on the mechanisms associated with postmenopausal vaginal symptoms will use state of the art microbiologic techniques on longitudinally collected biologic specimens and will guide future translational studies.
Specific Aim #2 addresses common problems for many midlife women and their providers: a) menopausal symptom management decisions can be challenging, due to rapidly changing and sometimes contradictory data on treatment safety and efficacy; and b) individualized decision aids to help women feel fully informed about various menopausal treatment options are lacking. To translate and disseminate our findings on postmenopausal vaginal health, in addition to findings from prior trials on vasomotor, sleep, mood and pain symptoms, we propose to develop and pilot test a comprehensive, state-of- the-art, tailored, multi-media materials aimed at facilitating informed menopausal decision-making for symptomatic women and their providers. Involvement of midlife women and healthcare providers at every stage in the process has been incorporated. This application is novel and transformative for: 1) proposing the first adequately powered, double-blind, placebo-controlled trial of hormonal and non-hormonal treatments for postmenopausal vaginal symptoms; and 2) for providing the first, multi-media menopause decision aid that encompasses the latest evidence surrounding all available therapies.
These aims are geared to transforming the evidence-base and resources available to aging women for navigating midlife and beyond.

Public Health Relevance

This is a new application from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network. Here we propose to conduct a large multicenter trial comparing two common treatments, a vaginal hormone pill and an over-the-counter gel, with placebo to evaluate their effects on bothersome vaginal symptoms and sexual function, and to create a biorepository of specimens for future translational, mechanistic research on the etiology of vaginal symptoms. We also propose to build a set of comprehensive, evidence-based, user friendly and widely available multi-media materials to reach women and providers with the newest trial results evaluating the effectiveness of treatments ranging from hormones to complementary and alternative therapies to behavioral interventions for relief of hot flashes, vaginal, sleep, mood and pain symptoms. These aims are geared to transforming the evidence-base and resources available to aging women for navigating this life stage.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG048209-01A1
Application #
8885435
Study Section
Special Emphasis Panel (ZAG1-ZIJ-3 (J3))
Program Officer
Hannah, Judy S
Project Start
2015-08-15
Project End
2020-03-31
Budget Start
2015-08-15
Budget End
2016-03-31
Support Year
1
Fiscal Year
2015
Total Cost
$1,400,000
Indirect Cost
$422,470
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Diem, Susan J; Guthrie, Katherine A; Mitchell, Caroline M et al. (2018) Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial. Menopause 25:1086-1093
Mitchell, Caroline M; Reed, Susan D; Guthrie, Katherine A (2018) Good Clinical Practice in Diagnosis of Vulvovaginal Symptoms-Reply. JAMA Intern Med 178:1136-1137
Mitchell, Caroline M; Reed, Susan D; Guthrie, Katherine A (2018) Time to advocate for better science, and better treatments for women. Menopause 25:1065-1068
Mitchell, Caroline M; Reed, Susan D; Diem, Susan et al. (2018) Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Intern Med 178:681-690